Cargando…
The Effect of Pembrolizumab in Absence of Programmed Death 1 Receptor
Tumor therapy has evolved greatly since the discovery of immunotherapies. New therapies permit targeted approach with less side effects. Immunotherapies target specific components recognized on tumor cells, such as Programmed death-1 (PD-1). Overexpression of PD-1 markers in solid gastrointestinal t...
Autores principales: | Al Attar, Layth, Truong, Phu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6263492/ https://www.ncbi.nlm.nih.gov/pubmed/30510858 http://dx.doi.org/10.7759/cureus.2896 |
Ejemplares similares
-
Cheerios Floating on Lung Computed Tomography Scan Revealing Cholangiocarcinoma of the Lungs
por: Al Attar, Layth, et al.
Publicado: (2018) -
Association of Celiac Disease With Pembrolizumab
por: Sethi, Ashish, et al.
Publicado: (2021) -
Acute Pancreatitis Secondary to Pembrolizumab-Induced Hypertriglyceridemia
por: Ashfaq, Ammar, et al.
Publicado: (2023) -
Neurotoxicity: A Rare Side Effect of Programmed Cell Death 1 (PD-1) Inhibitors
por: Ehsanullah, Syed, et al.
Publicado: (2022) -
Effectiveness and Safety of Pembrolizumab in Recurrent and Relapsed Classic Hodgkin Lymphoma: A Systematic Review
por: Hossain, Md Fahad, et al.
Publicado: (2023)